Sweden

The Swedish biotech has held positive talks with US regulators about the Phase III design for its pancreatic cancer candidate, mitazalimab. Now it needs to pin down a partner.

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.

Drug companies are being invited to participate in a new pilot project that the five Nordic countries will run to see if they can improve the availability of certain critical products that are used in hospitals.

European cross-country HTA collaborations have much to learn from each other to keep prices from rising unfairly, Nordic health technology assessment experts say, adding that talks on collaboration are also ongoing with HTA bodies outside the continent.

European cross-country HTA collaborations have much to learn from each other to keep drug prices from rising unfairly, Nordic health technology assessment experts say, adding that talks on collaboration are also ongoing with HTA bodies outside the continent.

It is time for companies to take part in cross-country health technology assessments and stop only asking “what’s in it for me?”

It is time for companies to take part in cross-country health technology assessments and stop asking “what’s in it for me?”

OTC erectile dysfunction treatment Eroxon has made it to the Nordics through local distributor Navamedic, which has reported strong consumer uptake.

Cash is king for fledgling biosimilar companies. Xbrane Biopharma has revealed just how close it is to the edge after Biogen unexpectedly pulled the plug on a key licensing deal, but the company is maintaining optimism.

UK regulator the Food Standards Agency intends to assess the risks associated with consuming supplements containing ashwagandha and to determine whether a safe level of the herb can be established. The launch of the consultation follows warnings from regulators across Europe about the safety of ashwagandha, with its consumption linked to a number of adverse health effects.